Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  thalidomide
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 45 for your search:
Start Over
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SHCZH-2010-CT-001, NCT01249690
Treatment of Peripheral T-cell Lymphoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-3, NCT01664975
Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18 to 74
Sponsor: Other
Protocol IDs: DREAM-002, NCT02401971
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 80
Sponsor: Other
Protocol IDs: A-39/29.1.2007, ICMR No-5/8/7/26/99-ECD-I, NCT00522405
Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: RFA005, NCT00728078
Autologous Transplant for Multiple Myeloma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2004LS001, MT2003-13, 0312M54569, UMN-2004LS001, UMN-MT2003-13, UMN-0312M54569, NCT00293306, NCT00177047
Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 12 to 70
Sponsor: Other
Protocol IDs: ICMR- D.O No.5/8/7/26/99-ECD-1, NCT01438450
Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 80
Sponsor: Other
Protocol IDs: TAC-HCC, NCT02240771
Gefitinib Combined With Thalidomide to Treat NSCLC
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: Over 18 to less than 75
Sponsor: Other
Protocol IDs: GELI, NCT02387086
UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2008-01, NCT00734877
Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MHOPES-myeloma09, NCT00892346
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: LCI-THALIDOMIDE, LCI-09-06-15, NCT00921531
Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT number: 2009-010956-93, NCT01554852
Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 5 to 18
Sponsor: Other
Protocol IDs: IEC/NP-63/2013, NCT01858571
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: NKT-SYSUCC-2013, NCT02085655
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CLOG1302, NCT02203253
Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NAB20140324, NCT02248428
Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 70
Sponsor: Other
Protocol IDs: 931003, NCT00155272
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HM12/10174, NCT02145715
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: T-CID, NCT00124813
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: KMM55, NCT00319865
TCD Followed by autoSCT for Newly Diagnosed MM Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: KMM53, NCT00349115
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: KMM51, 26866138MMY2028, NCT00378755
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FEMH-94037, NCT00384800
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: TMZ/05, P04932, NCT00521482
Start Over